Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

NCT ID	NCT04513717
Title	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Recruitment	Recruiting
Gender	male
Phase	Phase III
Variant Requirements	No
Sponsors	NRG Oncology
Indications	prostate adenocarcinoma
Therapies	Bicalutamide + Buserelin Buserelin + Flutamide Abiraterone + Apalutamide + Degarelix + Prednisone Abiraterone + Apalutamide + Buserelin + Prednisone Flutamide + Triptorelin Degarelix + Flutamide Abiraterone + Apalutamide + Leuprolide + Prednisone Flutamide + Leuprolide Flutamide + Goserelin Abiraterone + Apalutamide + Histrelin acetate + Prednisone Bicalutamide + Triptorelin Bicalutamide + Goserelin Flutamide + Histrelin acetate Bicalutamide + Degarelix Abiraterone + Apalutamide + Goserelin + Prednisone Abiraterone + Apalutamide + Prednisone + Triptorelin Bicalutamide + Leuprolide Bicalutamide + Histrelin acetate
Age Groups:	adult \| senior
Covered Countries	USA